We are live on ! Find out more
CBAY

Cymabay Therapeutics
CBAY

Delisted

CBAY was delisted on the 21st of March, 2024.

Back to rankings

27 hedge funds and large institutions have $12.7M invested in Cymabay Therapeutics in 2016 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 4 increasing their positions, 11 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 3

4% more funds holding

Funds holding: 26 → 27 (+1)

2% more capital invested

Capital invested by funds: $12.4M → $12.7M (+$266K)

33% less funds holding in top 10

Funds holding in top 10: 3 → 2 (-1)

64% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 11

Holders
27
Holders Change
+1
Holders Change %
+3.85%
% of All Funds
0.72%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.05%
New
4
Increased
4
Reduced
11
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
VKH
Virtu KCG Holdings
New York
+$34.2K
2
Goldman Sachs
Goldman Sachs
New York
+$32.9K
3
Barclays
Barclays
United Kingdom
+$22.9K
4
Vanguard Group
Vanguard Group
Pennsylvania
+$4.88K
5
Morgan Stanley
Morgan Stanley
New York
+$2.19K

Top Sellers

Rank Fund Capital Flow
1
OFM
Omega Fund Management
Massachusetts
-$606K
2
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$436K
3
LOAMU
Lombard Odier Asset Management (USA)
New York
-$52.2K
4
UCFA
United Capital Financial Advisors
Texas
-$52K
5
AllianceBernstein
AllianceBernstein
Tennessee
-$48.2K
Name Holding Trade Value Shares
Change 		Change in
Stake
A
1
Abingworth
United Kingdom
$3.1M – – –
VVM
2
Versant Venture Management
California
$2.03M – – –
KCM
3
Kingdon Capital Management
New York
$1.86M – – –
Adage Capital Partners
4
Adage Capital Partners
Massachusetts
$1.36M -$436K -219,200 -24%
LOAMU
5
Lombard Odier Asset Management (USA)
New York
$1.22M -$52.2K -26,238 -4%
Vanguard Group
6
Vanguard Group
Pennsylvania
$1.19M +$4.88K +2,456 +0.4%
OFM
7
Omega Fund Management
Massachusetts
$585K -$606K -304,623 -50%
AllianceBernstein
8
AllianceBernstein
Tennessee
$409K -$48.2K -24,243 -10%
Renaissance Technologies
9
Renaissance Technologies
New York
$234K -$14.9K -7,500 -6%
Geode Capital Management
10
Geode Capital Management
Massachusetts
$190K – – –
BFA
11
BlackRock Fund Advisors
California
$128K -$450 -226 -0.3%
BIT
12
BlackRock Institutional Trust
California
$90K – – –
Northern Trust
13
Northern Trust
Illinois
$58K – – –
ACI
14
Alpha Cubed Investments
California
$39K – – –
Bank of New York Mellon
15
Bank of New York Mellon
New York
$35K -$7.15K -3,596 -16%
VKH
16
Virtu KCG Holdings
New York
$33K +$34.2K +17,208 New
Goldman Sachs
17
Goldman Sachs
New York
$32K +$32.9K +16,554 New
Citadel Advisors
18
Citadel Advisors
Florida
$25K -$28.6K -14,358 -53%
Barclays
19
Barclays
United Kingdom
$22K +$22.9K +11,500 New
BIM
20
BlackRock Investment Management
Delaware
$7K +$547 +275 +8%
UBS Group
21
UBS Group
Switzerland
$6K -$6.22K -3,128 -51%
AIM
22
Acrospire Investment Management
Illinois
$5K -$597 -300 -10%
Parallax Volatility Advisers
23
Parallax Volatility Advisers
California
$3K -$11.2K -5,610 -76%
Morgan Stanley
24
Morgan Stanley
New York
$3K +$2.19K +1,100 +367%
Manulife (Manufacturers Life Insurance)
25
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$1K – – –
1
2

CBAY Hedge Fund Activity: Q3 2016 in Review

27 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Cymabay Therapeutics (CBAY) for Q3 2016, worth a combined $12.7M — up 2.1% from $12.4M a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new CBAY positions and 3 closed out — a net gain of 1 holder — while 4 added to existing stakes and 11 trimmed.

The largest buyer was Virtu KCG Holdings, opening a new position worth an estimated $34.2K. The largest seller was Omega Fund Management, cutting an estimated $606K.

  • 27 institutional investors held Cymabay Therapeutics (CBAY) as of Q3 2016, up from 26 in Q2 2016.
  • Funds reported $12.7M of Cymabay Therapeutics stock for Q3 2016, up 2.1% quarter-over-quarter.
  • 4 funds opened new Cymabay Therapeutics positions in Q3 2016 and 3 closed out, a net change of +1 holder.
  • The largest Cymabay Therapeutics buyer in Q3 2016 was Virtu KCG Holdings, an estimated $34.2K added.
  • The largest Cymabay Therapeutics seller in Q3 2016 was Omega Fund Management, an estimated $606K sold.

Based on aggregated 13F filings for Q3 2016.